Další formáty:
BibTeX
LaTeX
RIS
@article{1137569,
author = {Horák, Pavel and Skácelová, Martina and Hejduk, Karel and Smržová, Andrea and Pavelka, Karel},
article_location = {New York},
article_number = {10},
doi = {http://dx.doi.org/10.1007/s10067-013-2303-6},
keywords = {Abatacept; Registry; Rheumatoid arthritis},
language = {eng},
issn = {0770-3198},
journal = {Clinical Rheumatology},
title = {Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry},
volume = {32},
year = {2013}
}
TY - JOUR
ID - 1137569
AU - Horák, Pavel - Skácelová, Martina - Hejduk, Karel - Smržová, Andrea - Pavelka, Karel
PY - 2013
TI - Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry
JF - Clinical Rheumatology
VL - 32
IS - 10
SP - 1451-1458
EP - 1451-1458
PB - Springer
SN - 07703198
KW - Abatacept
KW - Registry
KW - Rheumatoid arthritis
N2 - The Czech national registry ATTRA collects data from patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis, treated with the biologic drugs. ATTRA is a prospective centralized computerized registry of patients with a focus on efficacy, safety, and quality of life data. Abatacept is approved as a second-line agent which can be prescribed after a failure of at least one TNF-alfa inhibitor. Data of patients treated with abatacept has been collected since 2008. A statistical analysis of the group of RA patients treated with abatacept was performed recently. ATTRA registered 162 patients with RA treated with abatacept, the mean age 51.0 +/- 12.2 (median 53.1, 19-74 years), the mean duration of the disease was 14 +/- 9.1, median 11.3 years (0-41). One hundred thirty patients (80.2 %) were female. The mean DAS28 was at week 0, 5.9 +/- 1.1, at week 16, 4.1 +/- 1.4, at week 24, 3.8 +/- 1.2, at week 36, 3.6 +/- 1.3, and at week 52, 3.5 +/- 1.2. DAS28 remission was achieved at week 16 in 15.8 %, at week 24 in 10 %, at week 36 in 20.9 %, and at week 52 in 20.8 % of patients. Of those patients with a DAS28 < 2.6 (remission) at week 16, 58.3 % remained in remission at the week 52. Of those patients with DAS28 > 5.1 (high disease activity) at the week 16, only 41.7 % had DAS > 5.1 at week 52. One year on treatment survival was 82 %. Altogether 50 non-serious adverse events (AE) were reported in 36 patients (22 %) and 11 serious AE in 10 patients (6 %) with the most common being infections (31) and skin rashes (5). Just one non-serious allergic reaction was reported. Data from the ATTRA registry confirms a good overall efficacy and safety profile and a very good on drug survival with abatacept.
ER -
HORÁK, Pavel, Martina SKÁCELOVÁ, Karel HEJDUK, Andrea SMRŽOVÁ a Karel PAVELKA. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. \textit{Clinical Rheumatology}. New York: Springer, roč.~32, č.~10, s.~1451-1458. ISSN~0770-3198. doi:10.1007/s10067-013-2303-6. 2013.
|
